title: Lipid-lowering Therapy in Patients With High Cardiovascular Risk: Dose or Combination?
abstract: Cardiovascular disease is the leading cause of death in the world. Dyslipidemia, manifested by elevated low-density lipoprotein cholesterol (LDL-C) levels, is central to the development and progression of atherosclerosis. Dyslipidemia has become a primary target of intervention in strategies for the prevention of cardiovascular events. Therapeutic lifestyle changes, such as increased physical activity, weight loss, smoking cessation, and adoption of a healthier diet, are effectively reducing cardiovascular risk in primary and secondary prevention. The combination therapy lowered LDL-C levels and achieved the LDL-C target in patients with high cardiovascular risk.
authors.affiliation: Department of Clinical Research, Federal University of Uberlândia, Uberlândia, Brazil. Electronic address: leonardoroever@hotmail.com.
authors.forename: Leonardo
authors.initials: L
authors.lastname: Roever
authors.affiliation: Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy; Department of AngioCardioNeurology, IRCCS Neuromed, Pozzilli, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Biondi-Zoccai
authors.affiliation: Duke Clinical Research Institute, Durham, North Carolina.
authors.forename: Sunil V
authors.initials: SV
authors.lastname: Rao
mesh_terms: D050197:Atherosclerosis / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D008078:Cholesterol, LDL / Q000097:blood; D050171:Dyslipidemias / Q000188:drug therapy*; D006801:Humans; D008019:Life Style; D012307:Risk Factors; D055502:Secondary Prevention
chemical_list: D008078:Cholesterol, LDL
keywords: cardiovascular risk; dyslipidemia; lipids; statins